



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
13.10.2021 Bulletin 2021/41

(45) Date of publication and mention
of the grant of the patent:
08.09.2021 Bulletin 2021/36

(21) Application number: **17711673.8**

(22) Date of filing: **21.03.2017**

(51) Int Cl.:
C07D 401/12^(2006.01) A61K 31/4725^(2006.01)
A61P 25/28^(2006.01)

(86) International application number:
PCT/EP2017/056696

(87) International publication number:
WO 2017/162674 (28.09.2017 Gazette 2017/39)

(54) **NOVEL DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2**

NEUARTIGE DERIVATE UND DEREN VERWENDUNG ALS SELEKTIVE
CASPASE-2-INHIBITOREN

NOUVEAUX DÉRIVÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS SÉLECTIFS DE
CASPASE-2

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **22.03.2016 EP 16305318**

(43) Date of publication of application:
30.01.2019 Bulletin 2019/05

(73) Proprietors:
• **Institut National de la Santé et de la**
Recherche Médicale (INSERM)
75013 Paris (FR)
• **Université de Paris**
75006 Paris (FR)

(72) Inventor: **JACOTOT, Etienne**
75005 Paris (FR)

(74) Representative: **Cousin, Geoffroy**
Fidal Innovation
4-6, avenue de l'Alsace
92400 Courbevoie (FR)

(56) References cited:
WO-A1-2014/026882

- **MICHEL C MAILLARD ET AL: "Exploiting differences in caspase-2 and -3 S2 subsites for selectivity: Structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 19, no. 19 16 August 2011 (2011-08-16), pages 5833-5851, XP002715860, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2011.08.020 Retrieved from the Internet: URL:http://www.sciencedirect.com/science/article/pii/S0968089611006547 [retrieved on 2011-08-16] cited in the application**
- **CHAUVIER ET AL.: "Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitor", CELL DEATH AND DISEASE, vol. 2, no. e203, 2011, pages 1-11, XP002758421, cited in the application**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- POREBA ET AL.: "Small molecule active site directed tools for studying human caspases", CHEM. REV., vol. 115, 2015, pages 12546-12629, XP002758422, cited in the application

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification